Patent · US Active

E-prostanoid receptor, Ptger3, as a novel anti-diabetic therapeutic target

US9381176B2 · kind B2 · utility

0Cited by

0References

19Claims

0Family size

Assignee

Wisconsin Alumni Research Foundation · US

Inventors

Mark Keller · McFarland, US
Alan Attie · Madison, US
Michelle Kimple · Chapel Hill, US

Key dates

Filing date	Feb 22, 2013
Grant date	Jul 5, 2016
Priority date	—
Expiry date	Feb 22, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P7/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods for increasing insulin secretion from beta cells. Also provide herein are methods comprising administering to a subject in need of increased insulin secretion a composition comprising a compound that directly or indirectly activates adenylate cyclase and an E prostanoid 3 (EP3) receptor antagonist that attenuates G alpha-i-subfamily (GSIS)-mediated adenylate cyclase inhibition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.